Zetia, Nustendi (ezetimibe) is a small molecule pharmaceutical. Ezetimibe was first approved as Zetia on 2002-10-25. It is used to treat familial combined hyperlipidemia, hypercholesterolemia, and hyperlipoproteinemia type II in the USA. It has been approved in Europe to treat dyslipidemias and hypercholesterolemia. The pharmaceutical is active against NPC1-like intracellular cholesterol transporter 1. Zetia's patents are valid until 2025-10-30 (FDA).
|Indication||dyslipidemias, familial combined hyperlipidemia, hypercholesterolemia, hyperlipoproteinemia type ii|
|Drug Class||Antihyperlipidaemics, acyl CoA: cholesterol acyltransferase (ACAT)inhibitors|